3 completed, 3 unknown, 3 withdrawn, 1 not yet recruiting. 8 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 3, Unknown 2, Withdrawn 2, Not yet recruiting 1 |
| Phase 3 | 2 | Unknown 1, Withdrawn 1 |
Follow UB-421: new trials by email Literature Review of UB-421 trials Research Report on UB-421
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 Infection UB-421 - Multi-Drug Resistant Hiv-1 Infection, HIV-1 Infection | Phase 2 | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-07-10 | 2025-07-11 | |
| To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults UB-421, current standard HAART treatment - HIV-1 Infection | Phase 3 | Withdrawn | United BioPharma | 2025-04-01 | 2023-04-25 | |
| A Proof of Concept Study to Evaluate the Effect of UB-421 in Combination With Chidamide on HIV Viral Reservoir UB-421, UB-421+chidamide - HIV-1-infection | Phase 2 | Not yet recruiting | UBP Greater China (Shanghai) Co., Ltd | 20 | 2024-03-01 | 2023-05-10 |
| UB-421 in Combination With Optimized Background Regimen in Patients With Multi-drug Resistant HIV-1 Infection UB-421, Antiretroviral (ARV) - HIV-1 Infection | Phase 3 | Unknown | United BioPharma | 50 | 2023-12-01 | 2023-04-24 |
| UB-421 Combine With Optimized Background Therapy Regimen in Multi-Drug Resistant HIV-1 Infection Patients UB-421, Optimized background therapy (OBT) - HIV-1 Infection | Phase 2 | Unknown | United BioPharma | 10 | 2023-12-01 | 2023-04-24 |
| The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients UB-421(25 mg/kg) Q2W, UB-421(25 mg/kg) Q4W - HIV-1-infection | Phase 2 | Unknown | UBP Greater China (Shanghai) Co., Ltd | 39 | 2023-12-01 | 2022-05-18 |
| A Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV Reservoirs UB-421, chidamide - HIV-1 Infection | Phase 2 | Completed | United BioPharma | 11 | 2021-12-02 | 2023-02-15 |
| the Study to Evaluate the Safety of UB-421 in Combination With Antiretroviral Therapy (ART) and the Efficacy in Reduction of HIV Viral Load and Proviral DNA as Compared to ART Alone in ART-experienced Viremic HIV-1 Patients UB-421, Antiretroviral Therapy (ART) - HIV-1 Infection | Phase 2 | Withdrawn | United BioPharma | 2020-04-01 | 2020-02-21 | |
| The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients UB-421(25 mg/kg) Q2W, UB-421(25 mg/kg) Q4W - HIV-1 Infection | Phase 2 | Completed | United BioPharma | 31 | 2018-12-12 | 2022-05-13 |
| To Investigate the Safety and Efficacy of UB-421 Monotherapy in HIV Infected Adults UB-421 - HIV-1 Infection | Phase 2 | Completed | United BioPharma | 29 | 2015-06-01 | 2017-10-31 |
United BioPharma (7) · UBP Greater China (Shanghai) Co., Ltd (2) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
Taiwan (3) · China (1) · United States (1)
Hung Chin Tsai, M.D. PhD. (1) · Michael C Sneller, M.D. (1) · Wing Wai Wong, M.D. (1) · Yen Hsu Chen, M.D. PhD. (1)